118 related articles for article (PubMed ID: 18981691)
1. [Antineovascular gene therapy by Ago2 knockdown].
Hatanaka K; Shimizu K; Asai T; Oku N
Yakugaku Zasshi; 2008 Nov; 128(11):1567-75. PubMed ID: 18981691
[TBL] [Abstract][Full Text] [Related]
2. Disappearance of the angiogenic potential of endothelial cells caused by Argonaute2 knockdown.
Asai T; Suzuki Y; Matsushita S; Yonezawa S; Yokota J; Katanasaka Y; Ishida T; Dewa T; Kiwada H; Nango M; Oku N
Biochem Biophys Res Commun; 2008 Apr; 368(2):243-8. PubMed ID: 18222171
[TBL] [Abstract][Full Text] [Related]
3. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system.
Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Ohga N; Hida K; Harashima H
J Control Release; 2014 Jan; 173():110-8. PubMed ID: 24120854
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles.
Vader P; Crielaard BJ; van Dommelen SM; van der Meel R; Storm G; Schiffelers RM
J Control Release; 2012 Jun; 160(2):211-6. PubMed ID: 21983283
[TBL] [Abstract][Full Text] [Related]
5. Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78.
Katanasaka Y; Ishii T; Asai T; Naitou H; Maeda N; Koizumi F; Miyagawa S; Ohashi N; Oku N
Int J Cancer; 2010 Dec; 127(11):2685-98. PubMed ID: 20178102
[TBL] [Abstract][Full Text] [Related]
6. Argonaute 2 promotes angiogenesis via the PTEN/VEGF signaling pathway in human hepatocellular carcinoma.
Ye ZL; Huang Y; Li LF; Zhu HL; Gao HX; Liu H; Lv SQ; Xu ZH; Zheng LN; Liu T; Zhang JL; Jin HJ; Qian QJ
Acta Pharmacol Sin; 2015 Oct; 36(10):1237-45. PubMed ID: 25937637
[TBL] [Abstract][Full Text] [Related]
7. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment.
Yonenaga N; Kenjo E; Asai T; Tsuruta A; Shimizu K; Dewa T; Nango M; Oku N
J Control Release; 2012 Jun; 160(2):177-81. PubMed ID: 22019557
[TBL] [Abstract][Full Text] [Related]
8. Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC.
Asai T; Miyazawa S; Maeda N; Hatanaka K; Katanasaka Y; Shimizu K; Shuto S; Oku N
Cancer Sci; 2008 May; 99(5):1029-33. PubMed ID: 18294280
[TBL] [Abstract][Full Text] [Related]
9. Development of a miR-92a delivery system for anti-angiogenesis-based cancer therapy.
Ando H; Okamoto A; Yokota M; Shimizu K; Asai T; Dewa T; Oku N
J Gene Med; 2013 Jan; 15(1):20-7. PubMed ID: 23239404
[TBL] [Abstract][Full Text] [Related]
10. Advanced cancer therapy by integrative antitumor actions via systemic administration of miR-499.
Ando H; Asai T; Koide H; Okamoto A; Maeda N; Tomita K; Dewa T; Minamino T; Oku N
J Control Release; 2014 May; 181():32-9. PubMed ID: 24593893
[TBL] [Abstract][Full Text] [Related]
11. Structurally modulated codelivery of siRNA and Argonaute 2 for enhanced RNA interference.
Li J; Wu C; Wang W; He Y; Elkayam E; Joshua-Tor L; Hammond PT
Proc Natl Acad Sci U S A; 2018 Mar; 115(12):E2696-E2705. PubMed ID: 29432194
[TBL] [Abstract][Full Text] [Related]
12. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
13. CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery.
Egorova A; Shubina A; Sokolov D; Selkov S; Baranov V; Kiselev A
Int J Pharm; 2016 Dec; 515(1-2):431-440. PubMed ID: 27789364
[TBL] [Abstract][Full Text] [Related]
14. VEGF siRNA delivered by polycation liposome-encapsulated calcium phosphate nanoparticles for tumor angiogenesis inhibition in breast cancer.
Chen J; Sun X; Shao R; Xu Y; Gao J; Liang W
Int J Nanomedicine; 2017; 12():6075-6088. PubMed ID: 28860767
[TBL] [Abstract][Full Text] [Related]
15. Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes.
Katanasaka Y; Ida T; Asai T; Maeda N; Oku N
Int J Pharm; 2008 Aug; 360(1-2):219-24. PubMed ID: 18565703
[TBL] [Abstract][Full Text] [Related]
16. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting tumor growth by targeting liposomally encapsulated CDC20siRNA to tumor vasculature: therapeutic RNA interference.
Majumder P; Bhunia S; Bhattacharyya J; Chaudhuri A
J Control Release; 2014 Apr; 180():100-8. PubMed ID: 24556418
[TBL] [Abstract][Full Text] [Related]
18. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing.
Cardoso AL; Simões S; de Almeida LP; Pelisek J; Culmsee C; Wagner E; Pedroso de Lima MC
J Gene Med; 2007 Mar; 9(3):170-83. PubMed ID: 17351968
[TBL] [Abstract][Full Text] [Related]
19. Dual receptor-specific peptides modified liposomes as VEGF siRNA vector for tumor-targeting therapy.
Yang Z; Xiang B; Dong D; Wang Z; Li J; Qi X
Curr Gene Ther; 2014; 14(4):289-99. PubMed ID: 25039617
[TBL] [Abstract][Full Text] [Related]
20. DICER-ARGONAUTE2 complex in continuous fluorogenic assays of RNA interference enzymes.
Bernard MA; Wang L; Tachado SD
PLoS One; 2015; 10(3):e0120614. PubMed ID: 25793518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
